By Therapeutic Area

Thyroid Eye Disease (TED) & Orbital Inflammation Market Analysis

Cross-industry research covering Thyroid Eye Disease (TED) & Orbital Inflammation across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports

1 Industries

Reports Covering Thyroid Eye Disease (TED) & Orbital Inflammation

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

TED biologic therapy is the highest-growth sub-segment, anchored by approved anti-IGF-1R therapy and a four-asset pipeline including VRDN-003 (Phase 3, NCT06625411) and linsitinib (Phase 2b/3, NCT05276063). Gross-to-net erosion from PBM rebate demands will compress net realized revenue, but WAC-level growth remains exceptional through 2029.

22%

Market Share

17.8%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments